Loading…
Drugs Made In America Acquisition Corp. is projected to rise to $12.40 by 2027, a +16% move from its current price of $10.71. DMAA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $10.68 | $10.71 | $10.74 | +0.02% |
| Aug 4 | $10.67 | $10.71 | $10.75 | +0.04% |
| Aug 5 | $10.67 | $10.72 | $10.76 | +0.05% |
| Aug 6 | $10.66 | $10.72 | $10.77 | +0.07% |
| Aug 7 | $10.66 | $10.72 | $10.78 | +0.09% |
| Aug 8 | $10.65 | $10.72 | $10.79 | +0.11% |
| Aug 9 | $10.65 | $10.72 | $10.80 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.65 | $10.72 | $10.80 | +0.13% |
| Week 2 | $10.63 | $10.74 | $10.84 | +0.26% |
| Week 3 | $10.62 | $10.75 | $10.88 | +0.39% |
| Week 4 | $10.62 | $10.77 | $10.92 | +0.51% |
| Week 5 | $10.61 | $10.78 | $10.95 | +0.64% |
| Week 6 | $10.61 | $10.79 | $10.98 | +0.77% |
| Week 7 | $10.61 | $10.81 | $11.01 | +0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Drugs Made In America Acquisition Corp. is a financial services company incorporated in 2024 and based in New York, New York. It does not have significant operations and intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses.
The current price is $10.69. The market capitalization is $259.52M and the company is ranked 3530. The forecast landscape suggests a multiyear upside with the average price rising across years from $10.69 in 2026 toward higher levels through 2050, including a 2050 avg of $94.80 and a max of $156.45.
A major floor 2.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 0.5% above — clearing it would confirm fresh momentum.
Key DMAA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMAA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.71 | Buy | $10.71 | Buy |
| MA 10 | $10.70 | Buy | $10.70 | Buy |
| MA 20 | $10.68 | Buy | $10.68 | Buy |
| MA 50 | $10.64 | Buy | $10.65 | Buy |
| MA 100 | $10.59 | Buy | $10.59 | Buy |
| MA 200 | $10.48 | Buy | $10.50 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.20 | Neutral |
| Stoch RSI (14) | 89.30 | Sell |
| CCI (20) | 90.91 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 0.28 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 65.30 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 10.71 | Sell |
| ADX (14) | 32.44 | Buy |
| ATR (14) | 0.01 | Info |
The near-term picture is bullish. RSI(14) is 60. The stock trades above the SMA50 at $10.63 and above the SMA200 at $10.47, with a near-term support at $10.60 and resistance at $10.70. The 30-day range runs from $10.62 to $10.76 and annualized volatility is 2%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.37 | $10.71 | $13.45 | 0% | Neutral | |
| $10.16 | $12.40 | $15.82 | +16% | Neutral | |
| $11.53 | $14.35 | $18.82 | +34% | Bullish | |
| $13.40 | $16.94 | $22.71 | +58% | Bullish | |
| $16.06 | $20.59 | $28.10 | +92% | Bullish | |
| $16.84 | $21.85 | $30.31 | +104% | Bullish | |
| $17.13 | $22.48 | $31.63 | +110% | Bullish | |
| $18.73 | $24.86 | $35.44 | +132% | Bullish | |
| $19.67 | $26.36 | $38.04 | +146% | Bullish | |
| $21.77 | $29.46 | $43.00 | +175% | Bullish | |
| $30.79 | $43.49 | $66.57 | +306% | Bullish | |
| $62.72 | $95.18 | $156.31 | +789% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $10.37 | $10.71 | $12.59 | +0.00% |
| September 2026 | $8.98 | $10.53 | $12.63 | -1.68% |
| October 2026 | $9.24 | $10.89 | $13.16 | +3.42% |
| November 2026 | $9.41 | $11.13 | $13.54 | +2.23% |
| December 2026 | $9.27 | $11.00 | $13.45 | -1.20% |
Click any year to see its month-by-month DMAA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, DMAA is projected to trade between $10.37 and $13.45, averaging $10.71 — a potential gain of 0% from today's $10.71. Price action looks broadly range-bound.
Drugs Made In America Acquisition Corp.'s 2027 outlook centres on $12.40, within a $10.16 to $15.82 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, DMAA could reach as high as $18.82, with a base case around $14.35 and support toward $11.53 — roughly +34% from $10.71. Momentum favours further upside here.
Expect DMAA to range from $13.40 to $22.71 through 2029. The $16.94 average target implies a +58% move from current prices. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The DMAA price prediction for 2030 points to an average of $20.59 (low $16.06, high $28.10) — a potential gain of +92% on today's $10.71. Momentum favours further upside here.
In 2031, DMAA is projected to trade between $16.84 and $30.31, averaging $21.85 — a potential gain of +104% from today's $10.71. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Drugs Made In America Acquisition Corp.'s 2032 outlook centres on $22.48, within a $17.13 to $31.63 range. That is up +3% on the projected 2031 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2033, DMAA could reach as high as $35.44, with a base case around $24.86 and support toward $18.73 — roughly +132% from $10.71. Buyers look set to stay in control over this stretch.
Expect DMAA to range from $19.67 to $38.04 through 2034. The $26.36 average target implies a +146% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The DMAA price prediction for 2035 points to an average of $29.46 (low $21.77, high $43.00) — a potential gain of +175% on today's $10.71. Buyers look set to stay in control over this stretch.
In 2040, DMAA is projected to trade between $30.79 and $66.57, averaging $43.49 — a potential gain of +306% from today's $10.71. That is up +48% on the projected 2035 average. Momentum favours further upside here.
Drugs Made In America Acquisition Corp.'s 2050 outlook centres on $95.18, within a $62.72 to $156.31 range. That is up +119% on the projected 2040 average. That marks a +789% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in DMAA today (≈ 93.370682 DMAA) could be worth
$8,886.97
+$7,886.97 (+789%) by 2050 · US Dollar
Based on the average projected DMAA price of $95.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMAAwould be worth at today's price.
$1,000 invested in DMAA on Jul 31, 2025 (≈ 97.370979 DMAA) would be worth
$1,042.84
+$42.84 (+4.3%) today · 1.04× · US Dollar
Based on a DMAA entry price of $10.27 vs. today's $10.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.7 | $1,000.93 | +0.1% |
| 1 month ago | $10.64 | $1,006.58 | +0.7% |
| 3 months ago | $10.57 | $1,013.25 | +1.3% |
| 6 months ago | $10.44 | $1,025.86 | +2.6% |
| 1 year ago | $10.27 | $1,042.84 | +4.3% |
| All time (1.4y) ago | $9.96 | $1,075.3 | +7.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMAA forecast.
Our base-case forecast reaches $21.00 around 2031.
Implied market cap at $21.00: $509.82M
The year-by-year forecast shows a persistent rise after 2026. The 2026 average is $10.69, then $12.45 in 2027 and $20.70 in 2030, with a 2030 max of $28.34 and a ROI of 93.7; sentiment BULLISH. By 2040 the average is $43.11, and by 2050 the average is $94.80 with a max of $156.45 and a ROI of 786.8; sentiment remains BULLISH.
These figures imply meaningful upside potential but are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $20.70, a min of $16.12 and a max of $28.34, with a ROI of 93.7 and sentiment BULLISH.
Forecasts show a bullish longer-term trajectory with higher averages and a ROI of 786.8 by 2050, though the 2026 year is NEUTRAL; these are estimates and not guarantees.
Yes. The forecast max reaches $66.26 in 2040 and $156.45 in 2050, while earlier years peak below 50 (2035 max $42.81).
Current price is $10.69 and market capitalization is $259.52M.
The 2026 forecast shows an average price of $10.69, a min of $10.37, and a max of $13.43, with ROI 0 and sentiment NEUTRAL.
Drugs Made In America Acquisition Corp. Community Discussion
0Share your Drugs Made In America Acquisition Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.